Unknown

Dataset Information

0

HDL Glycoprotein Composition and Site-Specific Glycosylation Differentiates Between Clinical Groups and Affects IL-6 Secretion in Lipopolysaccharide-Stimulated Monocytes.


ABSTRACT: The goal of this pilot study was to determine whether HDL glycoprotein composition affects HDL's immunomodulatory function. HDL were purified from healthy controls (n?=?13), subjects with metabolic syndrome (MetS) (n?=?13), and diabetic hemodialysis (HD) patients (n?=?24). Concentrations of HDL-bound serum amyloid A (SAA), lipopolysaccharide binding protein (LBP), apolipoprotein A-I (ApoA-I), apolipoprotein C-III (ApoC-III), ?-1-antitrypsin (A1AT), and ?-2-HS-glycoprotein (A2HSG); and the site-specific glycovariations of ApoC-III, A1AT, and A2HSG were measured. Secretion of interleukin 6 (IL-6) in lipopolysaccharide-stimulated monocytes was used as a prototypical assay of HDL's immunomodulatory capacity. HDL from HD patients were enriched in SAA, LBP, ApoC-III, di-sialylated ApoC-III (ApoC-III2) and desialylated A2HSG. HDL that increased IL-6 secretion were enriched in ApoC-III, di-sialylated glycans at multiple A1AT glycosylation sites and desialylated A2HSG, and depleted in mono-sialylated ApoC-III (ApoC-III1). Subgroup analysis on HD patients who experienced an infectious hospitalization event within 60 days (HD+) (n?=?12), vs. those with no event (HD-) (n?=?12) showed that HDL from HD+ patients were enriched in SAA but had lower levels of sialylation across glycoproteins. Our results demonstrate that HDL glycoprotein composition, including the site-specific glycosylation, differentiate between clinical groups, correlate with HDL's immunomodulatory capacity, and may be predictive of HDL's ability to protect from infection.

SUBMITTER: Krishnan S 

PROVIDER: S-EPMC5347119 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

HDL Glycoprotein Composition and Site-Specific Glycosylation Differentiates Between Clinical Groups and Affects IL-6 Secretion in Lipopolysaccharide-Stimulated Monocytes.

Krishnan Sridevi S   Shimoda Michiko M   Sacchi Romina R   Kailemia Muchena J MJ   Luxardi Guillaume G   Kaysen George A GA   Parikh Atul N AN   Ngassam Viviane N VN   Johansen Kirsten K   Chertow Glenn M GM   Grimes Barbara B   Smilowitz Jennifer T JT   Maverakis Emanual E   Lebrilla Carlito B CB   Zivkovic Angela M AM  

Scientific reports 20170313


The goal of this pilot study was to determine whether HDL glycoprotein composition affects HDL's immunomodulatory function. HDL were purified from healthy controls (n = 13), subjects with metabolic syndrome (MetS) (n = 13), and diabetic hemodialysis (HD) patients (n = 24). Concentrations of HDL-bound serum amyloid A (SAA), lipopolysaccharide binding protein (LBP), apolipoprotein A-I (ApoA-I), apolipoprotein C-III (ApoC-III), α-1-antitrypsin (A1AT), and α-2-HS-glycoprotein (A2HSG); and the site-s  ...[more]

Similar Datasets

2014-01-31 | GSE54558 | GEO
| S-EPMC2884165 | biostudies-literature
2014-01-31 | E-GEOD-54558 | biostudies-arrayexpress
| S-EPMC6113402 | biostudies-literature
| S-EPMC348798 | biostudies-literature
| S-EPMC5669101 | biostudies-literature
2003-03-10 | GSE105 | GEO
| S-EPMC3811771 | biostudies-literature
| S-EPMC6683009 | biostudies-literature
| S-EPMC3471934 | biostudies-literature